Cellectar Biosciences, Inc.
- CLRB
- NASDAQ
- Biotechnology
- Phospholipid Drug Conjugate
- Radiopharmaceuticals
- Cancer Therapeutics
$1.12
Today −1.75%Quote Oct 19, 2026, 08:00 PM UTC
−52.10%over the last month
Max drawdown −52.1%From 1-month high −52.1%3 months −55.8%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Cellectar Biosciences
Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
11
Market value
$10.6M
Quote Oct 19
Analyst target
$11.00
+882.1% from here
Floor
$0.97
13.1% below price
Resistance
$1.29
14.9% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about CLRBPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free